June 24, 2021 10:27 AM EDTUpdated 10:45 AM
Deals

Roche sev­ers ties with 4D Mol­e­c­u­lar Ther­a­peu­tics over blind­ness gene ther­a­py, mark­ing an­oth­er set­back for the field

Max Gelman

Senior Editor

Roche is turn­ing its nose up over a gene ther­a­py pro­gram tar­get­ing an in­her­it­ed form of night blind­ness, sig­nal­ing the lat­est set­back for such treat­ments …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times